Recent advancements in the arena of therapeutic molecular enhancement have shown favorable clinical findings for periodontics. However, further studies to optimize clinical outcomes using this technology are warranted. Twelve premolar extraction sockets were assigned randomly for treatment with 0.3 mg/mL recombinant human platelet-derived growth factor (rhPDGF-BB) combined with either a collagen containing anorganic deproteinized bovine bone (xenograft) or betatricalcium phosphate (ß-TCP). Histologic evaluation of extraction socket healing was performed at 3 months. Histologic findings were similar with ß-TCP and the xenograft, having 21% and 24% vital bone, respectively. The use of rhPDGF-BB with either ß-TCP or a xenograft resulted in uneventful socket healing. At reentry, all implants were placed without the need for further grafting, and 100% implant success was recorded at the time of final evaluation (restoration completion).